Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT05613894 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Cabozantinib

Sponsor

University of Utah

Collaborators

[object Object]